Purple Biotech Reports Interim Results From Randomized Phase 2 Pancreatic Cancer Study; Says Concordant And Consistent Improvement In Primary And All Secondary Endpoints Are Compelling
Purple Biotech Reports Interim Results From Randomized Phase 2 Pancreatic Cancer Study; Says Concordant And Consistent Improvement In Primary And All Secondary Endpoints Are Compelling
Purple Biotech發佈從隨機2期胰腺癌研究中獲得的中期結果，稱一致並且持續的主要和所有次要效應指標的改善非常具有說服力。
Purple Biotech Reports Interim Results From Randomized Phase 2 Pancreatic Cancer Study; Says Concordant And Consistent Improvement In Primary And All Secondary Endpoints Are Compelling
Purple Biotech發佈從隨機2期胰腺癌研究中獲得的中期結果，稱一致並且持續的主要和所有次要效應指標的改善非常具有說服力。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。